Latest stories on DWTX
Dogwood completes patient enrollment in Halneuron trial
The Fly63 · neutralproduct/pr
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
Business Insider63 · neutralproduct/pr
H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy
Investing.com Analyst Ratings61 · neutralanalyst
Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript
Seeking Alpha63 · neutralproduct/pr
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
Business Insider56 · neutralproduct/pr
Dogwood Therapeutics, Inc. (DWTX) files 8-K
SEC 8-K50 · neutralgeneral
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
Business Insider55 · neutralgeneral
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
GlobeNewswire55 · neutralgeneral
Keeping Pets Safe This Summer: What Every Owner Should Know
PR Newswire50 · neutralgeneral
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
Business Insider56 · neutralproduct/pr
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board | DWTX Stock News
StockTitan63 · neutralproduct/pr
Dogwood Therapeutics, Inc. (DWTX) files 8-K
SEC 8-K50 · neutralgeneral
Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript
Seeking Alpha50 · neutralgeneral
StratusGrid Raises $3M Seed Round to Advance AI-Driven Cloud Infrastructure Optimization
PR Newswire52 · neutralgeneral
Dogwood Therapeutics GAAP EPS of -$0.15
Seeking Alpha34 · bearishearnings